Plasma neutrophil gelatinase-associated lipocalin and kidney graft outcome

Daan Kremer, Adrian Post, António W Gomes-Neto, Dion Groothof, Setor K Kunutsor, Tom Nilsen, Clara Hidden, Erling Sundrehagen, Michele F Eisenga, Gerjan Navis, Stephan J L Bakker, TransplantLines Investigators, Daan Kremer, Adrian Post, António W Gomes-Neto, Dion Groothof, Setor K Kunutsor, Tom Nilsen, Clara Hidden, Erling Sundrehagen, Michele F Eisenga, Gerjan Navis, Stephan J L Bakker, TransplantLines Investigators

Abstract

Background: Plasma neutrophil gelatinase-associated lipocalin (pNGAL) has been investigated extensively in acute kidney injury. This study investigated its pathophysiological significance and utility as marker for graft failure and mortality in stable kidney transplant recipients (KTR).

Methods: Baseline pNGAL was measured in 698 KTR (58% male, age 53 ± 13 years, estimated glomerular filtration rate 52.4 ± 20.4 mL/min/1.73 m2) at median 5.4 (interquartile range 1.8-12.0) years after transplantation, enrolled in the prospective TransplantLines Food and Nutrition Biobank and Cohort Study.

Results: pNGAL concentrations were higher in males, younger patients, patients with a deceased-donor kidney and higher serum creatinine. Independent of these, pNGAL was positively associated with urinary protein excretion, systemic inflammation parameters and calcineurin inhibitor use. During median follow-up of 5.3 (4.5-6.0) years, death-censored graft failure rates were 3.9%, 7.3% and 25.0% across increasing tertiles of pNGAL (Plog-rank < 0.001). Cox-regression analyses showed no independent associations of pNGAL with mortality, but strong associations with graft failure (hazard ratio, per doubling 4.16; 95% confidence interval 3.03-5.71; P < 0.001), which remained independent of adjustment for confounders. These associations were present only in patients with pre-existent proteinuria and poor kidney function.

Conclusions: pNGAL is associated with parameters of kidney graft damage and with graft failure. The latter association is particularly present in KTR with pre-existent poor kidney function and proteinuria. Trial Registration: ClinicalTrials.gov NCT02811835.

Keywords: graft failure; inflammation; kidney transplant; mortality.

© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.

Figures

FIGURE 1:
FIGURE 1:
Kaplan–Meier analyses for (A) death-censored graft survival and (B) patient survival across tertiles of pNGAL. P-values represent significance of differences between the groups, as assessed using log-rank tests.
FIGURE 2:
FIGURE 2:
Graphical representation of the association between pNGAL and risk of death-censored graft failure, based on a multivariable Cox proportional hazards regression analyses. The model was adjusted for the full model of age, sex, time after transplantation, eGFR, log2 24-h urinary protein excretion, anti-HLA class II antibodies, pre-emptive transplantation, history of rejection, history of cardiovascular disease, log2 leukocyte count and log2 hs-CRP, and presented in relation to the histogram of pNGAL. The blue line represents the hazard ratio and the shaded blue area about the line the associated pointwise 95% CI.
FIGURE 3:
FIGURE 3:
Forest plot for the association of pNGAL with death-censored graft failure in subgroups. The model was adjusted for the full model of age, sex, time after transplantation, eGFR, log2 24-h urinary protein excretion, anti-HLA class II antibodies, pre-emptive transplantation, history of rejection, history of cardiovascular disease, log2 leukocyte count and log2 hs-CRP.

References

    1. Van Loon E, Bernards J, Van Craenenbroeck AH et al. The causes of kidney allograft failure: more than alloimmunity. A viewpoint article. Transplantation 2020; 104: e46–e56
    1. Naesens M, Lerut E, Emonds MP et al. Proteinuria as a noninvasive marker for renal allograft histology and failure: an observational cohort study. J Am Soc Nephrol 2016; 27: 281–292
    1. Smith-Palmer J, Kalsekar A, Valentine W. Influence of renal function on long-term graft survival and patient survival in renal transplant recipients. Curr Med Res Opin 2014; 30: 235–242
    1. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997; 45: 17–23
    1. Mårtensson J, Bellomo RR. The rise and fall of NGAL in acute kidney injury. Blood Purif 2014; 37: 304–310
    1. Mishra J, Mori K, Ma Q et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004; 15: 3073–3082
    1. Buonafine M, Martinez-Martinez E, Jaisser Fric. More than a simple biomarker: the role of NGAL in cardiovascular and renal diseases. Clin Sci 2018; 132: 909–923
    1. Haase-Fielitz A, Haase M, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem 2014; 51: 335–351
    1. Van Den Berg E, Engberink MF, Brink EJ et al. Dietary protein, blood pressure and renal function in renal transplant recipients. Br J Nutr 2013; 109: 1463–1470
    1. American Diabetes Association . Standards of medical care in diabetes. Diabetes Care 2017; 40: S11–S24
    1. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612
    1. Salvagno GL, Ferrari A, Gelati M et al. Analytical validation of gentian NGAL particle-enhanced enhanced turbidimetric immunoassay (PETIA). Pract Lab Med 2017; 8: 60–64
    1. Loupy A, Aubert O, Orandi BJ et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ 2019; 366: l4923.
    1. Kuwabara T, Mori K, Mukoyama M et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 2009; 75: 285–294
    1. Ding H, He Y, Li K et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol 2007; 123: 227–234
    1. Yavas H, Sahin OZ, Ersoy R et al. Prognostic value of NGAL staining in patients with IgA nephropathy. Ren Fail 2013; 35: 472–476
    1. Haase M, Bellomo R, Devarajan P et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009; 54: 1012–124
    1. Bolignano D, Donato V, Coppolino G et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008; 52: 595–605
    1. Maisel AS, Wettersten N, van Veldhuisen DJ et al. Neutrophil gelatinase-associated lipocalin for acute kidney injury during acute heart failure hospitalizations: the AKINESIS study. J Am Coll Cardiol 2016; 68: 1420–1431
    1. Kim S, Kim HJ, Ahn HS et al. Is plasma neutrophil gelatinase-associated lipocalin a predictive biomarker for acute kidney injury in sepsis patients? A systematic review and meta-analysis. J Crit Care 2016; 33: 213–223
    1. Hall IE, Yarlagadda SG, Coca SG et al. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol 2010; 21: 189–197
    1. Nielsen MB, Krogstrup NV, Nieuwenhuijs-Moekeid GJ et al. P-NGAL day 1 predicts early but not one year graft function following deceased donor kidney transplantation—the context study. PLoS One 2019; 14: 1–14
    1. Van Den Akker EK, Hesselink DA, Manintveld OC et al. Neutrophil gelatinase-associated lipocalin, but not kidney injury marker 1, correlates with duration of delayed graft function. Eur Surg Res 2015; 55: 319–327
    1. Maier HT, Ashraf MI, Denecke C et al. Prediction of delayed graft function and long-term graft survival by serum and urinary neutrophil gelatinase–associated lipocalin during the early postoperative phase after kidney transplantation. PLoS One 2018; 13: 1–11
    1. Daniels LB, Barrett-Connor E, Clopton P et al. Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: the Rancho Bernardo Study. J Am Coll Cardiol 2012; 59: 1101–1109
    1. Damman K, van Veldhuisen DJ, Navis G et al. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 997–1000
    1. Winkelmayer WC, Lorenz M, Kramar R, Fodinger M, Horl WH, Sunder-Plassmann g. C-Reactive protein and body mass index independently predict mortality in kidney transplant recipients. Am J Transplant 2004; 4: 1148–1154
    1. Bleskestad IH, Thorsen IS, Jonsson G et al. The impact of calcineurin inhibitors on neutrophil gelatinase-associated lipocalin and fibroblast growth factor 23 in long-term kidney transplant patients. Clin Transplant 2017; 31: 1–6
    1. Bataille A, Abbas S, Semoun O et al. Plasma neutrophil gelatinase-associated lipocalin in kidney transplantation and early renal function prediction. Transplantation 2011; 92: 1024–1030
    1. Cai L, Rubin J, Han W, Venge P, Xu S. The origin of multiple molecular forms in urine of HNL/NGAL. Clin J Am Soc Nephrol 2010; 5: 2229–2235

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner